Abstract
Purpose of Review: To review the role of brain-derived neurotrophic factor (BDNF) in neuroplasticity related to schizophrenia and the recent findings that have been reported on the status of BDNF in patients with schizophrenia and its association with the clinical measures. Recent Findings: Peripheral BDNF levels have been found altered in first-episode patients with psychosis and also in chronic schizophrenia patients. A few studies have reported changes in peripheral BDNF levels following antipsychotic treatment. The role of Val66Met polymorphism in BDNF has been shown to play an important role in structural and functional plasticity in schizophrenia. Summary: Although peripheral BDNF levels hold promise for providing new perspectives for the development of novel therapeutic strategies for the treatment of schizophrenia, additional studies including efforts to prove its potential as a biomarker are warranted.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 122-127 |
| Number of pages | 6 |
| Journal | Current Opinion in Psychiatry |
| Volume | 24 |
| Issue number | 2 |
| DOIs | |
| State | Published - Mar 2011 |
Keywords
- Val66Met
- antipsychotic
- brain-derived neurotrophic factor
- neuroplasticity
- peripheral
- psychosis
- schizophrenia
ASJC Scopus subject areas
- Psychiatry and Mental health
